Albireo’s clinical pipeline includes three mid to late-stage product candidates that are designed to act locally to potentially restore normal bile acid levels and are being developed to treat diseases and disorders associated with irregularities in bile acid biology.


Products described on this Website, with the exception of elobixibat for chronic constipation in Japan, are investigational new drugs, and are not approved for use or commercially available.